FindTrial
Sign In

VPM1002

BIOLOGICAL8 trials

Sponsors

Serum Life Science Europe GmbH, Serum Institute of India Pvt. Ltd., University Health Network, Toronto, Serum Institute of India Private Limited

Conditions

HealthyInfection, Respiratory TractMycobacterium Tuberculosis InfectionSARS-CoV-2 InfectionTuberculosis

Phase 1

Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male Volunteers
CompletedNCT00749034
Serum Life Science Europe GmbHHealthy, Tuberculosis
Start: 2008-09-30End: 2009-12-31Updated: 2010-05-20

Phase 2

Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Newborn Infants in South Africa
CompletedNCT01479972
Serum Life Science Europe GmbHTuberculosis
Start: 2011-11-30End: 2012-11-30Updated: 2013-10-29
Study to Evaluate the Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa
CompletedNCT02391415
Serum Institute of India Pvt. Ltd.Tuberculosis
Start: 2015-06-30End: 2017-11-30Updated: 2018-04-18

Phase 3

Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants
CompletedNCT04351685
Serum Institute of India Pvt. Ltd.Mycobacterium Tuberculosis Infection
Start: 2020-11-09End: 2024-10-30Updated: 2025-02-10
Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic
NCT04387409
Serum Life Science Europe GmbHInfection, Respiratory Tract
Start: 2020-05-25End: 2021-05-01Updated: 2020-09-30
Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic
CompletedNCT04435379
Serum Life Science Europe GmbHInfection, Respiratory Tract
Start: 2020-06-18End: 2021-10-12Updated: 2021-10-26
Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity
CompletedNCT04439045
University Health Network, TorontoSARS-CoV-2 Infection
Start: 2020-06-24End: 2021-09-09Updated: 2022-04-15
Study to Evaluate the Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Mycobacterium Tuberculosis Infection in Newborn Infants at multiple sites
Active, not recruitingPACTR202007868402718
Serum Institute of India Private LimitedTuberculosis
Start: 2020-10-31Target: 6940Updated: 2026-01-27

Related Papers

VPM1002 as Prophylaxis Against Severe Respiratory Tract Infections Including Coronavirus Disease 2019 in the Elderly: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study
Clinical Infectious Diseases2022-11-0931 citations
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial.
2022-06-2739 citations
Will bacille Calmette-Guerin immunization arrest the COVID-19 pandemic?
The Indian Journal of Medical Research2020-07-019 citations
Impact of Heart Rate Reduction with Maximal Tolerable Dose of Bisoprolol on Left Ventricular Reverse Remodeling
Journal of Korean Medical Science2018-01-014 citations
Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa
Clinical and Vaccine Immunology2017-01-09154 citations
Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial.
2013-01-03153 citations